The Pharmacokinetics of Racemic Verapamil in Patients with Impaired Renal Function

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Journal of clinical pharmacology

• Publication date

  1991-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/j.1552-4604.1991.tb01885.xPMID 2045528
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients.

  2009cited by this paper
• Pharmacokinetics of verapamil in patients with renal failure

  2004cited by this paper
• Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil

  2004cited by this paper
• Effects of verapamil and converting enzyme inhibition on bilateral renal function of two-kidney, one-clip hypertensive rats.

  1987cited by this paper
• Effects of verapamil alone and with captopril on blood pressure and bilateral renal function in Goldblatt hypertensive rats.

  1986cited by this paper
• Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses.

  1986cited by this paper
• Clarke's Isolation and Identification of Drugs

  1986cited by this paper
• Verapamil kinetics during maintenance hemodialysis.

  1985cited by this paper
• A review of metabolite kinetics

  1985cited by this paper
• Verapamil Worsens Rate of Development and Hemodynamic Effects of Acute Hyperkalemia in Halothane‐anesthetized Dogs: Effects of Calcium Therapy

  1984cited by this paper
• Effects of verapamil in models of ischemic acute renal failure in the rat.

  1983cited by this paper
• Ischemic acute renal failure--pathogenetic steps leading to acute tubular necrosis.

  1983cited by this paper
• Ischemic acute renal failure. Pathogenetic steps leading to acute tubular necrosis

  1983cited by this paper
• The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.

  1983cited by this paper
• Effects of calcium-entry antagonists in hypertension.

  1982cited by this paper
• The clinical use of verapamil.

  1982cited by this paper
• The Pharmacology of Verapamil. III. Pharmacokinetics in Normal Subjects After Intravenous Drug Administration

  1981cited by this paper
• Verapamil protein binding in patients and in normal subjects

  1981cited by this paper
• Verapamil disposition kinetics in chronic atrial fibrillation

  1981cited by this paper
• Verapamil kinetics in normal subjects and patients with coronary artery spasm

  1981cited by this paper
• The Effect of Verapamil on Mechanical Performance of Acutely Ischemic and Reperfused Myocardium in the Conscious Dog

  1981cited by this paper
• Principles and procedures of statistics: A biometrical approach

  1981cited by this paper
• Drug therapy in renal failure.

  1980cited by this paper
• High-performance liquid chromatographic analysis of verapamil. II. Simultaneous quantitation of verapamil and its active metabolite, norverapamil.

  1980cited by this paper
• Pharmacokinetics of verapamil in man.

  1979cited by this paper
• Drug therapy in renal failure.

  1979cited by this paper
• Physiological disposition of verapamil in man.

  1976cited by this paper
• Pharmacokinetics and Effects of Propranolol in Terminal Uraemic Patients and in Patients Undergoing Regular Dialysis Treatment

  1976cited by this paper
• Fundamentals of Clinical Pharmacokinetics

  1975cited by this paper
• Pharmacokinetics of oral propranolol in chronic renal disease

  1974cited by this paper
• Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

  1970cited by this paper

• Choosing the right calcium channel blocker for patients with hypertension and proteinuric chronic kidney disease

  2025cites this paper
• Verapamil-Induced Hypotension in End-Stage Renal Disease: The Role of Calcium Gluconate

  2023cites this paper
• Verapamil: prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients?

  2022cites this paper
• Extracorporeal treatment for calcium channel blocker poisoning: systematic review and recommendations from the EXTRIP workgroup

  2021cites this paper
• Efficacy of Various Antihypertensive Drugs in the Treatment of Hypertension in the Patients of End-Stage Renal Disease Leading to Haemodialysis- A Retrospective Study

  2017cites this paper
• Efficacy of various antihypertensive drugs in the treatment of hypertension in the patients of end-stage renal disease leading to hemodialysis: a retrospective study

  2017cites this paper
• Management of hypertension in patients with end-stage renal disease leading to haemodialysis: a challenge

  2016cites this paper
• Prediction of human drug clearance and anticipation of clinical drug-drug interaction potential from in vitro drug transport studies

  2014cites this paper
• The management of hypertension in hemodialysis and CAPD patients.

  2007cites this paper
• Verapamil and mild hyperkalemia in hemodialysis patients: A potentially hazardous association

  2006cites this paper
• Management of hypertension in hemodialysis patients

  2006cites this paper
• HPLC/MS findings in a fatality involving sustained-release verapamil

  2003cites this paper
• Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations

  2003cites this paper
• SIMULTANEOUS HPLC ANALYSIS OF S- AND R-VERAPAMIL AND METABOLITES, S- AND R-NORVERAPAMIL IN HUMAN PLASMA

  2000cites this paper
• ACC/AHA guidelines for coronary artery bypass graft surgery

  1999cites this paper
• Absolute bioavailability estimated from oral data.

  1995cites this paper
• Effect of renal failure on drug metabolism by the liver.

  1993cites this paper
• [Poisoning by delayed-release verapamil in an uremic patient].

  1992cites this paper
• Management of Hypertension in the End-Stage Renal Disease Patient

  year unknowncites this paper